News | Stroke | April 07, 2021

Thrombectomy Market Will Grow With Newly Approved Adjustable Stent Retriever

GlobalData market research says thrombectomy devices will reach $465 million in 2025

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.

April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices), shows the U.S. thrombectomy device market is worth about $265 million in 2020 and is predicted to grow to $465 million by 2025. The data and analytics company said this this growth will be driven by an increase in thrombectomy procedures and the newly approved adjustable stent retriever device.

There are two types of devices for extracting stroke-causing clots in the arteries of the brain — stent retrievers and aspiration catheters. These devices can be used individually or in combination. While the clinical outcomes and revascularization rates is similar for both the device, used separately or in conjugation, the aspiration retriever is quicker and easier to operate and is therefore becoming more popular.

The U.S. Food and Drug Administration (FDA) recently approved Rapid Medical’s TigerTriever, the first adjustable stent retriever approved in the U.S. The approval followed promising results from the device's multi-center trial. The TigerTriever’s main advantage over current stent retrievers is that the diameter of the basket, where a clot is caught and extracted, can be adjusted via a slide on the handle of the device. This allows neuro interventional operators greater control over the procedure, increasing patient compatibility and potentially lowering the risk of clot fragmentation.

“Mechanical thrombectomy has become increasingly popular in recent years compared to managing stroke patients using medical managements, as early clinical studies suggest that it potentially leads to improved clinical outcomes," said Dominic Tong, medical devices analyst at GlobalData. "Stent retrievers aim to trap a clot within their basket, allowing the clots to be removed from the blood vessel, while aspiration catheters rely on suction to remove the clots."

Tong said any innovations that further increase the efficacy and safety of mechanical thrombectomy are welcome. With continual improvements, he said mechanical thrombectomy may eventually overtake medical management as the preferred treatment for some cases.

“Additionally, while the thrombectomy market has been relatively resilient through the COVID-19 pandemic, it still experienced a drop in revenue that was potentially due to increased hospital load making it harder for operations to happen within eight hours of symptom onset. As vaccines rollout and hospitals return to business as usual, Rapid Medical has an opportunity to capitalize on the rebounding market and capture more market share during this period of recovery,” Tong said.

Among the near thrombectomy companies mentioned in the report are:
   • Cerenovus
   • Medtronic plc
   • phenox GmbH
   • MicroVention Inc
   • Stryker Neurovascular
   • Imperative Care Inc
   • Penumbra Inc
   • Balt Extrusion SAS
   • Acandis GmbH & Co KG

For more information: https://store.globaldata.com/report/gdme572mm--neurovascular-thrombectomy-devices-neurology-devices-global-market-analysis-and-forecast-model-covid-19-market-impact/?utm_source=email&utm_medium=pr&utm_campaign=210407a_gd_md_thrombectomy_devices_market&utm_nooveride=1

For more news on thrombectomy systems

Related Content

Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar